Efruxifermin (AKR-001) is an investigational drug developed by Akero Therapeutics, acting as a fibroblast growth factor 21 (FGF21) analog developed to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), and type 2 diabetes.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.